Securities Investigation – SignPath Pharma
Are you concerned about your investment in SignPath Pharma? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.
SignPath Pharma, Inc., a clinical stage biotechnology company, focuses on the research and development of curcumin formulations for the treatment of cancer, cardiac, and neurologic disorders, according to Bloomberg. The company was founded in 2006 and is based in Center Valley, Pennsylvania.
The company has filed a Form D to raise capital from investors, according to SEC filings. Investments such as these are typically sold by brokerage firms in exchange for a large up front commission. High fees can range from 7-10%, as well as additional “due diligence fees” that can range from 1-3%.
According to filings with the SEC, SignPath Pharma filed a Form D in 2016. The total offering amount was $5,000,000 with an estimated 10% paid in sales commissions, according to the Form D.
Private placements investments are a means for smaller companies to raise capital through the sale of equity or debt securities without having to register their securities with the SEC. These investments are often riskier and more complicated than traditional investments, and are only suitable for high net worth, sophisticated investors.
Is a Private Placement Investment Suitable for you?
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly selling high-risk private placements, like SignPath Pharma, to their clients.
Despite the risks of investing in private placements, brokerage firms continue to push this type of investment because of the high commissions associated with their sale and creation.
Prior to making recommendations to an individual investor, brokerage firms are required by the Financial Industry Regulatory Authority (FINRA) to disclose all the risks of an investment. Recommendations should only be made if the investment is suitable for an individual investor given their age, investment objections, investment experience and risk tolerance.
Brokerage firms that do not perform adequate due diligence on an investment and/or make unsuitable recommendations can be held accountable for investment losses through FINRA arbitration.
Are you concerned about your investment in SignPath Pharma? If so, The White Law Group may be able to help. Please call the offices at 888-637-5510 for a free consultation with a securities attorney.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.
For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.
[maxbutton id=”1″ ]
Tags: SignPath Pharma complaints, SignPath Pharma high commissions, SignPath Pharma investigation, SignPath Pharma investment, SignPath Pharma investor relations, SignPath Pharma investors, SignPath Pharma IPO, SignPath Pharma losses, SignPath Pharma ppm, SignPath Pharma private placement, SignPath Pharma prospectus, SignPath Pharma recovery options, SignPath Pharma risk, SignPath Pharma update Last modified: April 8, 2019